Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · NOVAVAX INC (NVAX)

Novavax Q3 revenue slips 3% to $68 million; net loss narrows, revenue guidance raised

Positive Impact 4 of 5 earnings Written later

Novavax reported third-quarter 2026 total revenue of $68 million, down 3% from $70 million a year earlier, while its net loss narrowed to $31 million from $202 million. The company raised its full-year 2026 Adjusted Total Revenue guidance to $385 million to $415 million, up from $235 million to $275 million, mainly reflecting a $125 million Sanofi milestone earned in October 2026.

Key points

  • Q3 2026 total revenue was $68 million, versus $70 million in Q3 2025.
  • Q3 2026 net loss was $31 million, versus $202 million in Q3 2025.
  • Full-year 2026 Adjusted Total Revenue guidance raised to $385 million-$415 million from $235 million-$275 million.
  • Combined R&D and SG&A expense guidance narrowed to $375 million-$395 million from $370 million-$410 million.

The filing

CompanyNOVAVAX INC (NVAX)
Form8-K, current report
Filed with the SECNov 5, 2026, 8:08 AM ET
Accession number0001000694-26-000021

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.